Atu027 & gemcitabine in lead in safety period
Atu027-I-02
Phase 2 small_molecule completed
Quick answer
Atu027 & gemcitabine in lead in safety period for Carcinoma, Pancreatic Ductal is a Phase 2 program (small_molecule) at Silence Therapeutics plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Silence Therapeutics plc
- Indication
- Carcinoma, Pancreatic Ductal
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed